03.29.12
Almac and Affymetrix have signed an exclusive global distribution agreement allowing Affymetrix to sell Almac’s Xcel Array for biomarker discovery, development and delivery worldwide.
The Xcel array is a high-density transcriptome-based microarray that has been optimized for the discovery and development of biomarkers from formalin fixed paraffin embedded (FFPE) tissue. The array contains more than 97,000 transcripts including antisense, non-coding transcripts and significant unique content. Working with FFPE enables the potential to profile retrospective samples in tissue banks for potential discovery opportunities in personalized medicine.
Michael Sloan, vice president of business development of Almac’s Diagnostics Business Unit, said, “We are very pleased to have entered into this agreement with Affymetrix. The Xcel array has proven to be extremely useful in our hands for biomarker discovery both for our in-house R&D and for our clients. This distribution deal with Affymetrix will enable more researchers to see the benefit of the platform.”
The Xcel array is a high-density transcriptome-based microarray that has been optimized for the discovery and development of biomarkers from formalin fixed paraffin embedded (FFPE) tissue. The array contains more than 97,000 transcripts including antisense, non-coding transcripts and significant unique content. Working with FFPE enables the potential to profile retrospective samples in tissue banks for potential discovery opportunities in personalized medicine.
Michael Sloan, vice president of business development of Almac’s Diagnostics Business Unit, said, “We are very pleased to have entered into this agreement with Affymetrix. The Xcel array has proven to be extremely useful in our hands for biomarker discovery both for our in-house R&D and for our clients. This distribution deal with Affymetrix will enable more researchers to see the benefit of the platform.”